Geode Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,436,689
| Closed | -$34.6M | – | 4854 |
|
|
2023
Q1 | $34.6M | Buy |
1,436,689
+114,500
| +9% | +$1.44M | ﹤0.01% | 1439 |
|
|
2022
Q4 | $14M | Buy |
1,322,189
+125,392
| +10% | +$1.01M | ﹤0.01% | 2024 |
|
|
2022
Q3 | $5.38M | Buy |
1,196,797
+241,548
| +25% | +$1.1M | ﹤0.01% | 2633 |
|
|
2022
Q2 | $3.82M | Sell |
955,249
-11,491
| -1% | -$54.5K | ﹤0.01% | 2840 |
|
|
2022
Q1 | $7.08M | Buy |
966,740
+11,406
| +1% | +$68.2K | ﹤0.01% | 2588 |
|
|
2021
Q4 | $5.37M | Sell |
955,334
-84,772
| -8% | -$538K | ﹤0.01% | 2861 |
|
|
2021
Q3 | $6.66M | Buy |
1,040,106
+99,502
| +11% | +$639K | ﹤0.01% | 2742 |
|
|
2021
Q2 | $7.93M | Buy |
940,604
+74,854
| +9% | +$604K | ﹤0.01% | 2625 |
|
|
2021
Q1 | $9.09M | Buy |
865,750
+152,127
| +21% | +$2.14M | ﹤0.01% | 2423 |
|
|
2020
Q4 | $12.1M | Buy |
713,623
+71,893
| +11% | +$1.08M | ﹤0.01% | 2035 |
|
|
2020
Q3 | $8.23M | Buy |
641,730
+87,571
| +16% | +$1.11M | ﹤0.01% | 2071 |
|
|
2020
Q2 | $7.82M | Buy |
554,159
+263,306
| +91% | +$3.32M | ﹤0.01% | 2078 |
|
|
2020
Q1 | $2.67M | Buy |
290,853
+36,668
| +14% | +$473K | ﹤0.01% | 2511 |
|
|
2019
Q4 | $3.79M | Sell |
254,185
-11,986
| -5% | -$107K | ﹤0.01% | 2616 |
|
|
2019
Q3 | $1.82M | Buy |
266,171
+96,409
| +57% | +$975K | ﹤0.01% | 2995 |
|
|
2019
Q2 | $2.05M | Buy |
+169,762
| New | +$924K | ﹤0.01% | 2933 |
|
Other funds holding PRVB
Geode Capital Management's PRVB Position: Q2 2023 in Review
Geode Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,436,689 shares — an estimated $34.6M sold.
Geode Capital Management first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $34.6M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Geode Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Geode Capital Management sold 1,436,689 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $34.6M.
- Geode Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Geode Capital Management's Provention Bio, Inc. Common Stock position peaked at $34.6M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.